Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

@article{Ramalingam2010PhaseIS,
  title={Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.},
  author={Suresh S Ramalingam and Shivaani Kummar and John Sarantopoulos and Stephen I. Shibata and Patricia Lorusso and Mara A Yerk and Julianne Holleran and Yan Lin and Jan Hendrik Beumer and Robert Donald Harvey and S Percy Ivy and Chandra Prakash Belani and Merrill J. Egorin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 29},
  pages={4507-12}
}
PURPOSE Vorinostat is the first US Food and Drug Administration-approved histone deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell lymphoma. We conducted a phase I study to determine the maximum-tolerated dose and pharmacokinetics of vorinostat in patients with hepatic dysfunction. PATIENTS AND METHODS Patients had solid malignancies and acceptable bone marrow and renal function. Hepatic dysfunction was categorized as mild, moderate, or severe by the… CONTINUE READING